Vir Biotechnology (NASDAQ:VIR) reported quarterly losses of $(1.17) per share which missed the analyst consensus estimate of $(0.84) by 39.29 percent. This is a 25 percent increase over losses of $(1.56) per share from the same period last year. The company reported quarterly sales of $240.000 thousand which missed the analyst consensus estimate of $1.983 million by 87.90 percent. This is a 89.92 percent decrease over sales of $2.380 million the same period last year.